Concord Medical - Spon ADRCCM
13F holders, Q1 2026 (March 31)4holders
1new positions
1sold out
$3.83avg. 13F price*
At the end of Q1 2026, 4 institutions reported holding Concord Medical - Spon ADR (CCM) in their 13F filings, unchanged from Q4 2025. 1 opened new positions and 1 sold out. The largest holders were Susquehanna International Group, LLP ($45K), UBS Group AG ($2K) and Morgan Stanley ($365).
- Company
- Concord Medical - Spon ADR
- CUSIP
- 206277204
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $45K |
| Exits | 1 | $0 |
All 13F filers, Q4 2025 → Q1 2026: 11,723 shares bought and 285 shares sold, net +11,438 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Susquehanna International Group, LLP | 0.00% | New | 11,723 | $45K |
| UBS Group AG | 0.00% | Reduce -28.7% | 615 | $2K |
| Morgan Stanley | 0.00% | No change | 100 | $365 |
| SBI Securities Co., Ltd. | 0.00% | No change | 4 | $15 |
"% of holder's portfolio" is CCM's weight in each manager's 13F, not the share of Concord Medical - Spon ADR the manager owns.